8-K Announcements
6Material company update
May 8, 2026·SEC
Material company update
Apr 24, 2026·SEC
Material company update
Mar 19, 2026·SEC
Humacyte, Inc.(HUMA)Earnings, Financials & Key Ratios
HUMA•NASDAQ
Price updated Jun 19, 2026
AboutHumacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.Show more
- Revenue$2M
- EBITDA-$100M+6.6%
- Net Income-$41M+72.5%
- EPS (Diluted)-0.26+79.4%
- Gross Margin-736.46%
- EBITDA Margin-4911.29%
- Operating Margin-5271.69%
- Net Margin-2003.58%
- ROE-1313.38%
HUMA Key Insights
Humacyte, Inc. (HUMA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓High quality earnings: Operating CF exceeds net income
✗Weaknesses
- ✗High debt to equity ratio of 20.9x
- ✗Negative free cash flow
- ✗Shares diluted 33.5% in last year
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 47.0x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when HUMA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
HUMA Price & Volume
Humacyte, Inc. (HUMA) stock price & volume — 10-year historical chart
Loading chart...
HUMA Growth Metrics
Humacyte, Inc. (HUMA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years6.45%
3 Years9.2%
TTM-73.97%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-25.65%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM14.64%
Return on Capital
10 Years-64.83%
5 Years-69.7%
3 Years-89.31%
Last Year-99.52%
HUMA Recent Earnings
Humacyte, Inc. (HUMA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 2/12 qtrs (29%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.09+10.0%
$0.10
Rev
$495,000-66.2%
$1M
Q2 2026
Mar 27, 2026Metric
Actual
Est
EPS
$0.13+0.0%
$0.13
Rev
$467,000-65.4%
$1M
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.14+17.6%
$0.17
Rev
$753,000-44.2%
$1M
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$0.24-60.0%
$0.15
Rev
$301,000-67.2%
$917,830
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.09vs $0.10+10.0% | $495,000vs $1M-66.2% |
| Q2 2026 | Mar 27, 2026 | $0.13vs $0.13+0.0% | $467,000vs $1M-65.4% |
| Q4 2025 | Nov 12, 2025 | $0.14vs $0.17+17.6% | $753,000vs $1M-44.2% |
| Q3 2025 | Aug 11, 2025 | $0.24vs $0.15-60.0% | $301,000vs $917,830-67.2% |
Based on last 12 quarters of dataView full earnings history →
HUMA Peer Comparison
Humacyte, Inc. (HUMA) competitors in Regenerative Medicine and Tissue Engineering — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 TELA | 36.85M | 0.82 | -0.99 | 15.84% | -49.3% | -13.44% | 8.82 | |
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 ATRC | 1.46B | 28.80 | -120 | 14.88% | -0.83% | -0.95% | 0.18 | |
 ANGO | 505.13M | 12.15 | -14.64 | -3.76% | -9.02% | -15.71% | ||
 AORT | 1.03B | 21.19 | 100.90 | 13.59% | 2.55% | 2.66% | 0.65 | |
 ELMD | 320.27M | 38.68 | 44.98 | 16.97% | 14.08% | 22.14% | 0.00 | |
 LMAT | 2.14B | 93.95 | 37.28 | 13.53% | 24.35% | 16.19% | 0.47 | |
 BDX | 52.16B | 143.98 | 24.70 | 8.23% | 5.33% | 4.54% | 0.76 |
Compare HUMA vs Peers
Humacyte, Inc. (HUMA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
HUMA Income Statement
Humacyte, Inc. (HUMA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 6.19M | 1.49M | 1.26M | 1.56M | 0 | 0 | 2.04M | 2.02M |
Revenue Growth % | - | -75.9% | -15.29% | 23.91% | -100% | - | - | -73.97% |
Cost of Goods Sold | 75.6M | 54.08M | 61.34M | 8.26M | 76.55M | 7.19M | 17.05M | 17.11M |
COGS % of Revenue | 1221.97% | 3626.96% | 4856.77% | 527.48% | - | - | 836.46% | - |
Gross Profit | -69.42M▲ 0% | -52.59M▲ 24.2% | -60.08M▼ 14.2% | -6.69M▲ 88.9% | -76.55M▼ 1044.2% | -7.19M▲ 90.6% | -15.01M▼ 108.7% | -15.09M▲ 0% |
Gross Margin % | -1121.97% | -3526.96% | -4756.77% | -427.48% | - | - | -736.46% | -748.51% |
Gross Profit Growth % | - | 24.24% | -14.24% | 88.86% | -1044.25% | 90.61% | -108.75% | - |
Operating Expenses | 16.27M | 12.01M | 21.13M | 77.89M | 23.5M | 107.21M | 92.43M | 98.8M |
OpEx % of Revenue | 263.05% | 805.7% | 1673% | 4976.87% | - | - | 4535.23% | - |
Selling, General & Admin | 16.27M | 12.01M | 21.13M | 22.88M | 20.39M | 25.8M | 31.17M | 27.31M |
SG&A % of Revenue | 263.05% | 805.7% | 1673% | 1462.17% | - | - | 1529.49% | - |
Research & Development | 75.6M | 54.08M | 61.34M | 63.26M | 76.55M | 88.6M | 69.3M | 73.35M |
R&D % of Revenue | 1221.97% | 3626.96% | 4856.77% | 4042.17% | - | - | 3400.49% | - |
Other Operating Expenses | -75.6M | -54.08M | -61.34M | -8.26M | -73.44M | -7.19M | -8.04M | -1000K |
Operating Income | -85.69M▲ 0% | -64.6M▲ 24.6% | -81.21M▼ 25.7% | -84.58M▼ 4.1% | -100.05M▼ 18.3% | -114.4M▼ 14.3% | -107.44M▲ 6.1% | -113.89M▲ 0% |
Operating Margin % | -1385.02% | -4332.66% | -6429.77% | -5404.35% | - | - | -5271.69% | -5649.21% |
Operating Income Growth % | - | 24.61% | -25.71% | -4.15% | -18.29% | -14.34% | 6.08% | - |
EBITDA | -78.94M | -56.25M | -72.97M | -76.37M | -92.33M | -107.21M | -100.09M | -106.58M |
EBITDA Margin % | -1275.93% | -3772.57% | -5777.28% | -4879.74% | - | - | -4911.29% | -5286.95% |
EBITDA Growth % | - | 28.75% | -29.72% | -4.66% | -20.9% | -16.12% | 6.64% | -2.75% |
D&A (Non-Cash Add-back) | 6.75M | 8.35M | 8.24M | 8.21M | 7.72M | 7.19M | 7.34M | 7.3M |
EBIT | -85.69M | -64.6M | -81.21M | -84.58M | -104.18M | -139.42M | -107.44M | -119.27M |
Net Interest Income | -2.03M | -1.92M | -4.33M | -3.57M | -1.13M | -5.17M | -8.66M | -8.27M |
Interest Income | 269K | 278K | 16K | 2.63M | 5.47M | 4.1M | 2.59M | 2.25M |
Interest Expense | 2.3M | 2.2M | 4.35M | 6.2M | 6.6M | 9.28M | 11.25M | 10.52M |
Other Income/Expense | 269K | -1.92M | 54.73M | 72.61M | -10.73M | -34.3M | 66.6M | 16.3M |
Pretax Income | -85.42M▲ 0% | -66.52M▲ 22.1% | -26.48M▲ 60.2% | -11.96M▲ 54.8% | -110.78M▼ 825.8% | -148.7M▼ 34.2% | -40.83M▲ 72.5% | -97.59M▲ 0% |
Pretax Margin % | -1380.67% | -4461.7% | -2096.36% | -764.54% | - | - | -2003.58% | -4840.82% |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -85.42M▲ 0% | -66.52M▲ 22.1% | -26.48M▲ 60.2% | -11.96M▲ 54.8% | -110.78M▼ 825.8% | -148.7M▼ 34.2% | -40.83M▲ 72.5% | -97.59M▲ 0% |
Net Margin % | -1380.67% | -4461.7% | -2096.36% | -764.54% | - | - | -2003.58% | -4840.82% |
Net Income Growth % | - | 22.12% | 60.2% | 54.81% | -825.83% | -34.24% | 72.54% | -25.65% |
Net Income (Continuing) | -85.42M | -66.52M | -26.48M | -11.96M | -110.78M | -148.7M | -40.83M | -97.59M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -4.25▲ 0% | -5.52▼ 29.9% | -0.66▲ 88.0% | -0.12▲ 81.8% | -1.07▼ 791.7% | -1.26▼ 17.8% | -0.26▲ 79.4% | -0.49▲ 0% |
EPS Growth % | - | -29.88% | 88.04% | 81.82% | -791.67% | -17.76% | 79.37% | 14.64% |
EPS (Basic) | -4.25 | -5.52 | -0.66 | -0.12 | -1.07 | -1.26 | -0.26 | - |
Diluted Shares Outstanding | 20.12M | 12.45M | 39.97M | 103.05M | 103.42M | 118.48M | 158.16M | 197.85M |
Basic Shares Outstanding | 20.12M | 12.45M | 39.97M | 103.05M | 103.42M | 118.48M | 158.16M | 197.85M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
HUMA Balance Sheet
Humacyte, Inc. (HUMA) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 94.95M | 41.45M | 229.34M | 154.21M | 83.28M | 47.86M | 67.8M | 63.6M |
Cash & Short-Term Investments | 93.71M | 39.93M | 225.5M | 151.88M | 80.45M | 44.94M | 50.5M | 48.54M |
Cash Only | 93.71M | 39.93M | 217.5M | 149.77M | 80.45M | 44.94M | 50.5M | 48.54M |
Short-Term Investments | 0 | 0 | 8M | 2.11M | 0 | 0 | 0 | 0 |
Accounts Receivable | 601K | 113K | 176K | 31K | 0 | 0 | 441K | 434K |
Days Sales Outstanding | 35.46 | 27.66 | 50.86 | 7.23 | - | - | 78.98 | 106.23 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 13.59M | 9.92M |
Days Inventory Outstanding | - | - | - | - | - | - | 290.96 | 282.69 |
Other Current Assets | 0 | 0 | 0 | 2.3M | 2.83M | 2.92M | 3.27M | 4.7M |
Total Non-Current Assets | 73.74M | 65.24M | 57.19M | 50.09M | 44.95M | 90.01M | 48.57M | 46.96M |
Property, Plant & Equipment | 73.74M | 65.24M | 57.19M | 50.09M | 44.1M | 38.55M | 47.69M | 46.08M |
Fixed Asset Turnover | 0.08x | 0.02x | 0.02x | 0.03x | - | - | 0.04x | 0.05x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 209K | 209K |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 841K | 51.46M | 672K | 881K |
Total Assets | 168.69M▲ 0% | 106.69M▼ 36.8% | 286.53M▲ 168.6% | 204.3M▼ 28.7% | 128.22M▼ 37.2% | 137.87M▲ 7.5% | 116.37M▼ 15.6% | 110.56M▲ 0% |
Asset Turnover | 0.04x | 0.01x | 0.00x | 0.01x | - | - | 0.02x | 0.02x |
Asset Growth % | - | -36.76% | 168.57% | -28.7% | -37.24% | 7.53% | -15.6% | -67.48% |
Total Current Liabilities | 10.84M | 11.23M | 11.05M | 19.58M | 18.44M | 19.95M | 18.37M | 16.19M |
Accounts Payable | 3.27M | 2.27M | 2.09M | 1.59M | 6.49M | 4.49M | 5.4M | 5.08M |
Days Payables Outstanding | 15.8 | 15.35 | 12.46 | 70.52 | 30.95 | 227.93 | 115.71 | 142.37 |
Short-Term Debt | 1.5M | 2.45M | 0 | 8.57M | 0 | 0 | 2.43M | 2.43M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | -1.5M | 1.15M | 4.12M | 4.23M | 5.29M | 7.37M | 10.54M | 8.68M |
Current Ratio | 8.76x | 3.69x | 20.75x | 7.88x | 4.52x | 2.40x | 3.69x | 3.93x |
Quick Ratio | 8.76x | 3.69x | 20.75x | 7.88x | 4.52x | 2.40x | 2.95x | 3.32x |
Cash Conversion Cycle | - | - | - | - | - | - | 254.23 | 246.55 |
Total Non-Current Liabilities | 25.65M | 24.78M | 153.31M | 67.79M | 96.23M | 170.59M | 94.89M | 82.75M |
Long-Term Debt | 0 | 822K | 27.36M | 20.34M | 38.6M | 0 | 35.44M | 63.47M |
Capital Lease Obligations | 25.65M | 23.82M | 21.79M | 18.85M | 16.29M | 13.62M | 26.97M | 66.16M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 144K | 104.16M | 28.61M | 41.34M | 156.97M | 32.47M | 19.27M |
Total Liabilities | 36.49M | 36.02M | 164.36M | 87.37M | 114.68M | 190.54M | 113.26M | 98.93M |
Total Debt | 28.72M | 28.86M | 51.18M | 50.07M | 57.45M | 16.54M | 64.85M | 65.9M |
Net Debt | -65M | -11.07M | -166.32M | -99.71M | -23M | -28.4M | 14.35M | 17.36M |
Debt / Equity | 0.22x | 0.41x | 0.42x | 0.43x | 4.24x | - | 20.86x | 5.67x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.62x |
Net Debt / EBITDA | - | - | - | - | - | - | - | -0.16x |
Interest Coverage | -37.29x | -29.34x | -18.68x | -13.64x | -15.79x | -15.03x | -9.55x | -11.34x |
Total Equity | 132.2M▲ 0% | 70.67M▼ 46.5% | 122.17M▲ 72.9% | 116.93M▼ 4.3% | 13.55M▼ 88.4% | -52.67M▼ 488.8% | 3.11M▲ 105.9% | 11.62M▲ 0% |
Equity Growth % | - | -46.54% | 72.87% | -4.29% | -88.42% | -488.82% | 105.9% | 245.02% |
Book Value per Share | 6.57 | 5.68 | 3.06 | 1.13 | 0.13 | -0.44 | 0.02 | 0.06 |
Total Shareholders' Equity | 132.2M | 70.67M | 122.17M | 116.93M | 13.55M | -52.67M | 3.11M | 11.62M |
Common Stock | 21K | 1K | 10K | 10K | 10K | 13K | 20K | 10.86M |
Retained Earnings | -321.57M | -388.1M | -414.57M | -426.54M | -537.31M | -686.01M | -726.85M | -744.47M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
HUMA Cash Flow Statement
Humacyte, Inc. (HUMA) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -71.79M | -55.57M | -81.19M | -71.13M | -73.31M | -98.12M | -105.04M | -101.54M |
Operating CF Margin % | -1160.29% | -3726.89% | -6428.35% | -4544.98% | - | - | -5154.17% | - |
Operating CF Growth % | - | 22.59% | -46.11% | 12.39% | -3.06% | -33.85% | -7.05% | -14.48% |
Net Income | -85.42M | -66.52M | -26.48M | -11.96M | -110.78M | -148.7M | -40.83M | -97.59M |
Depreciation & Amortization | 6.75M | 8.43M | 8.24M | 8.21M | 7.72M | 7.19M | 5.33M | 5.07M |
Stock-Based Compensation | 4.46M | 0 | 10.15M | 6.18M | 6.83M | 6.14M | 9.75M | 7.27M |
Deferred Taxes | -4.27M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 6.25M | 4.89M | -72.54M | -74.59M | 16.35M | 36.94M | -55.9M | -1.15M |
Working Capital Changes | 453K | -2.37M | -557K | 1.03M | 6.57M | 311K | -23.39M | -15.14M |
Change in Receivables | -185K | 488K | -63K | 145K | 31K | 0 | -261K | 54K |
Change in Inventory | -2.43M | 0 | 0 | 0 | 0 | 0 | -21.83M | -11.76M |
Change in Payables | 2.43M | -889K | -197K | -509K | 4.81M | -1.96M | 973K | -42K |
Cash from Investing | -8.13M | -268K | -8.22M | 4.84M | -173K | -1.57M | -884K | -831K |
Capital Expenditures | -8.13M | -318K | -220K | -1.05M | -2.28M | -1.57M | -884K | -831K |
CapEx % of Revenue | 131.32% | 21.33% | 17.42% | 66.96% | - | - | 43.38% | 41.22% |
Acquisitions | 0 | 50K | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | -74K | 2.05M | 266.98M | -1.45M | 4.51M | 114.18M | 61.49M | 38.07M |
Debt Issued (Net) | -1.29M | 1.75M | 27.93M | -1.98M | 5.7M | -2.58M | 36.38M | 37.07M |
Equity Issued (Net) | 0 | 301K | 0 | 0 | 566K | 89.05M | 113.44M | 92.94M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 1.22M | 0 | 239.05M | 535K | -1.76M | 27.71M | -88.34M | -91.94M |
Net Change in Cash | -79.99M▲ 0% | 39.93M▲ 149.9% | 177.57M▲ 344.7% | -67.73M▼ 138.1% | -69.18M▼ 2.1% | 14.49M▲ 120.9% | -44.44M▼ 406.7% | -64.45M▲ 0% |
Free Cash Flow | -79.91M▲ 0% | -55.89M▲ 30.1% | -81.41M▼ 45.7% | -72.18M▲ 11.3% | -75.58M▼ 4.7% | -99.69M▼ 31.9% | -105.93M▼ 6.3% | -102.38M▲ 0% |
FCF Margin % | -1291.61% | -3748.22% | -6445.76% | -4611.95% | - | - | -5197.55% | -5078.17% |
FCF Growth % | - | 30.07% | -45.67% | 11.34% | -4.72% | -31.9% | -6.25% | -1.58% |
FCF per Share | -3.97 | -4.49 | -2.04 | -0.70 | -0.73 | -0.84 | -0.67 | -0.52 |
FCF Conversion (FCF/Net Income) | 0.84x | 0.84x | 3.07x | 5.94x | 0.66x | 0.66x | 2.57x | 1.05x |
Interest Paid | 0 | 0 | 1.12M | 2.67M | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
HUMA Key Ratios
Humacyte, Inc. (HUMA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -65.58% | -27.46% | -10.01% | -169.81% | - | -1313.38% | -2781.56% |
Return on Invested Capital (ROIC) | -76.41% | -788.22% | - | -1930.66% | - | - | -334.92% |
Gross Margin | -3526.96% | -4756.77% | -427.48% | - | - | -736.46% | -748.51% |
Net Margin | -4461.7% | -2096.36% | -764.54% | - | - | -2003.58% | -4840.82% |
Debt / Equity | 0.41x | 0.42x | 0.43x | 4.24x | - | 20.86x | 5.67x |
Interest Coverage | -29.34x | -18.68x | -13.64x | -15.79x | -15.03x | -9.55x | -11.34x |
FCF Conversion | 0.84x | 3.07x | 5.94x | 0.66x | 0.66x | 2.57x | 1.05x |
Revenue Growth | -75.9% | -15.29% | 23.91% | -100% | - | - | -73.97% |
Related:HUMA Dividend History·HUMA Revenue History·HUMA Price History·HUMA P/E History·HUMA Financial Ratios·HUMA Institutional Holders
HUMA SEC Filings & Documents
Humacyte, Inc. (HUMA) SEC filings — annual & quarterly reports (10-K, 10-Q)
HUMA Frequently Asked Questions
Humacyte, Inc. (HUMA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Humacyte, Inc. (HUMA) reported $2.0M in revenue for fiscal year 2025. This represents a 67% decrease from $6.2M in 2019.
Humacyte, Inc. (HUMA) grew revenue by 0.0% over the past year. Growth has been modest.
Humacyte, Inc. (HUMA) reported a net loss of $97.6M for fiscal year 2025.
Dividend & Returns
Humacyte, Inc. (HUMA) has a return on equity (ROE) of -1313.4%. Negative ROE indicates the company is unprofitable.
Humacyte, Inc. (HUMA) had negative free cash flow of $102.4M in fiscal year 2025, likely due to heavy capital investments.